Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSEMKT: MSTX); Price Target $2.25
February 28 2014 - 09:00AM
Marketwired
Vista Partners Updates Coverage on Mast Therapeutics, Inc.
(NYSEMKT: MSTX); Price Target $2.25
Currently Enrolling Patients in Phase 3 Sickle Cell Clinical
Trial, Phase 2 ALI Clinical Trial Scheduled to Commence in Q1 2014,
Acquired Aires Pharmaceuticals, Inc.
SAN FRANCISCO, CA--(Marketwired - Feb 28, 2014) - Vista Partners
announced today that it has updated coverage on Mast Therapeutics
Inc. (NYSEMKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical
company headquartered in San Diego, CA; and maintains its
twelve-month price target of $2.25. Ross Silver, Principal Analyst
at Vista Partners, stated, "There has been considerable partnership
and M&A activity for companies working on Sickle Cell Disease.
On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an
agreement with Novartis Pharmaceuticals, the agreement with
Novartis could reach up to $665 million. In October 2011, Pfizer
signed a licensing deal with U.S. firm GlycoMimetics which may be
worth up to $340 million, including an upfront payment as well as
development, regulatory, and commercial milestones, plus
royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC),
the first biotech IPO of 2014, currently trades at a market cap of
around $225M whereas MSTX is around $85M. GlycoMimetics has only
completed a Phase 2 trial whereas MSTX is actively enrolling
patients in a Phase 3 trial."
To download a FREE copy of the Mast Therapeutics Inc. research
report, please visit http://www.vistapglobal.com and click the
"download research" icon to gain access to the report.
About Vista Partners: Vista Partners LLC, founded in 2005, is a
Registered Investment Advisor in the States of California and
Oregon. The firm's professional staff has backgrounds in finance,
corporate communications and investment banking.
Please follow Vista Partners on Twitter @VistaPResearch &
Facebook at Vista-Partners to receive updates, thoughts and ideas
about our coverage universe of companies.
Disclaimer & Disclosure: For a full list of disclaimers and
disclosures, please visit our website www.vistapglobal.com or click
here.
Contact: 877.215.4813 Email Contact
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Savara Inc. (AMEX:MSTX)
Historical Stock Chart
From Mar 2023 to Mar 2024